IMMVIRA CO LTD has a total of 17 patent applications. Its first patent ever was published in 2016. It filed its patents most often in Canada, Republic of Korea and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals and biotechnology are INNOVATIVE CELLULAR THERAPEUTICS CO LTD, AUTOLUS LTD and NANJING IASO BIOTHERAPEUTICS CO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | Canada | 3 | |
#2 | Republic of Korea | 3 | |
#3 | WIPO (World Intellectual Property Organization) | 3 | |
#4 | EPO (European Patent Office) | 2 | |
#5 | Israel | 2 | |
#6 | United States | 2 | |
#7 | China | 1 | |
#8 | New Zealand | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides | |
#4 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Chen Xiaoqing | 10 |
#2 | Zhou Grace Guoying | 9 |
#3 | Liu Xianjie | 8 |
#4 | Chen Mingjiu | 4 |
#5 | Tan Wei | 4 |
#6 | Roizman Bernard | 2 |
#7 | Zhou Grace | 2 |
#8 | Zhou Xusha | 1 |
#9 | Tang Yuxin | 1 |
#10 | Yan Runbin | 1 |
Publication | Filing date | Title |
---|---|---|
WO2021030932A1 | Pharmaceutical compositions comprising oncolytic herpes simplex virus for systemic administration | |
WO2021000309A1 | Pharmaceutical compositions, kits and methods for treating tumors | |
CN112074297A | Antibodies that bind PD-1 and uses thereof | |
CA3020243A1 | Exosomes carrying icp4-targeting mirna, pharmaceutical compositions and methods for treating hsv infection | |
WO2020034051A1 | Methods and compositions for treatment of solid cancers and microbial infection | |
EP3380621A1 | CONSTRUCTION OF ONCOLYTIC HERPES SIMPLEX VIRUSES (oHSV) OBLIGATE VECTOR AND CONSTRUCTS FOR CANCER THERAPY |